Garrick K. Packard

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Justin T. Ernst, Peggy A. Thompson, Christian Nilewski et al. · Journal of Medicinal Chemistry · 2020 · 145 citations · Full text

Life Sciences, Oncology, Pharmacology +16

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

Deborah S. Mortensen, Sophie Perrin-Ninkovic, Graziella Shevlin et al. · Journal of Medicinal Chemistry · 2015 · 73 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization

Deborah S. Mortensen, Kimberly E. Fultz, Shuichan Xu et al. · Molecular Cancer Therapeutics · 2015 · 53 citations · Full text

Medicine, Oncology, Pharmacology +14

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Peggy A. Thompson, Boreth Eam, Nathan P. Young et al. · Molecular Cancer Therapeutics · 2020 · 45 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer

Qun Li, Keith W. Woods, Sheela A. Thomas et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 38 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16